News

Vir and Gilead strike up to $1.9B deal for dual-masked T-cell engagers in solid tumours

What's the deal: Vir Biotechnology and Gilead Sciences announced on 14 October 2026 a collaboration and licence agreement to discover and develop three novel PRO-XTEN dual-masked T-cell engagers (TCEs) targeting solid tumour-associated antigens. Vir is responsible for the discovery, design and optimisation of the candidates; Gilead holds an exclusive licence to develop, manufacture and commercialise them.

Why it matters: T-cell engagers are engineered antibodies that physically link a cancer cell to a T cell so the immune system attacks the tumour. Vir's PRO-XTEN masking technology keeps the engager inactive until it reaches the tumour microenvironment, which is designed to limit the side effects that often limit these therapies. This is Vir's second collaboration built on the platform and a validation of its AI-enabled protein engineering, while it gives Gilead access to a pipeline of next-generation cancer immunotherapies.

Financial terms: Vir can receive up to $135 million in upfront and near-term preclinical payments — $90 million upfront, made up of $65 million in cash and a $25 million equity investment at a 30% premium — plus up to $45 million in near-term preclinical milestones. On top of that, Vir is eligible for up to $1.74 billion in development, regulatory and commercial milestones, and tiered high single-digit to low double-digit royalties on net sales, for a headline total of up to about $1.9 billion.

Read more: Vir Biotechnology via Business Wire, 14 October 2026 · Reuters, 14 October 2026

More top stories